Sichuan Sunheal Pharmaceutical

Sichuan Sunheal Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, dedicated to the discovery and development of novel small molecule therapeutics. The company focuses on high-prevalence disease areas, particularly oncology and metabolic disorders, utilizing a structure-based drug discovery platform to optimize lead compounds. Its lead clinical candidate, SH-1028, is a third-generation EGFR tyrosine kinase inhibitor designed to treat non-small cell lung cancer patients with the T790M mutation. Additionally, Sunheal is advancing SH-1573, a potent DPP-4 inhibitor for the treatment of type 2 diabetes, through late-stage clinical trials. The company aims to bridge the gap between innovative research and clinical application to deliver high-quality, accessible medicines for patients with unmet medical needs.